By altering the mRNA structure, researchers can create stable, non-immunogenic mRNA through in vitro transcription.

And this is precisely where the scientists's new strategy comes in. Based on the structure of the mRNA-binding protein, they have developed a large peptide, that can block the interaction of the ...

And this is precisely where the scientists' new strategy comes in. Based on the structure of the mRNA-binding protein, they ...

The idea that speckles might be storage sites for spliceosomes triggered Guttman to look deeper into how nuclear organization ...

Production tips from Crystal Bio, TriLink Biotechnologies, Ginkgo Bioworks, Quantoom Biosciences, and Parexel.

Nanoparticles have once again reached the spotlight, this time as a critical tool to combat the spread of covid-19. In this ...

Vaccine maker Moderna's chief executive officer Stephane Bancel will vacate his role as the company's chief commercial ...

Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...

Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03 Achieves year-to-date ...

Researchers uncovered a promising target for controlling gene expression, which could impact crop resilience and human disease treatment.

For mRNA decapping by enhancing DCP2's mRNA-binding affinity and regulating distinct biological processes through DCP1a and DCP1b, human DCP1 is essential.

Drug maker Moderna, Inc. (MRNA) reported Thursday that its third-quarter net income was $13 million, compared to a net loss of $3.63 ...